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To the Editor, 
 
The approved combination of ipilimumab and nivolumab (ipi + nivo) demonstrates 
potent clinical activity, including in patients with poor prognostic factors such as an 
elevated lactate dehydrogenase (LDH) [1]. In the subgroup with elevated LDH, the 
response rate is superior with the combination but its durability in this cohort is not 
established [2]. Neither the efficacy of ipi + nivo in treating brain metastases nor 
clinical outcomes of patients treated with ipi + nivo after primary progression on anti–
PD-1 therapy have been described. The extent to which high-dose steroids may 
reduce treatment efficacy is unclear—there is evidence that the response rate to 
anti–PD-1 agents in patients on corticosteroids or other immunomodulatory 
medications is worse; however, clinical benefit is not precluded [3]. 
In a recently published case series in this journal, Kirchberger et al. investigated the 
combination of low-dose ipilimumab (1 mg/kg) and pembrolizumab (2 mg/kg) in nine 
patients, who progressed after sequential single-agent pembrolizumab and 
ipilimumab. Out of nine, six patients had brain metastases but whether they were 
symptomatic is not described. No treatment-related adverse events occurred. Three 
out of nine patients achieved stable disease as their best response with progression-
free survival rates of 4, 6 and 14 months, respectively. No partial responses were 
seen [4]. However, the combination of ipilimumab plus pembrolizumab is currently 
not licenced for use in metastatic melanoma. 
We describe the case of a 27-year-old male with metastatic BRAF-mutant melanoma 
involving the brain and leptomeninges, in addition to visceral sites, who was treated 
with ipi + nivo following primary progression on pembrolizumab after four cycles. 
Before pembrolizumab, he received 10 months of dabrafenib and then progressed. 
He received whole-brain radiotherapy after the first cycle of pembrolizumab due to 
the symptomatic progression of central nervous system disease. At the initiation of 
ipi + nivo, his LDH was 312 (upper limit of normal (ULN) 192 U/L) and 
dexamethasone 4 mg twice a day (bd) was maintained due to ongoing symptomatic 
brain oedema. On days 6 and 9 of cycle 1 ipi + nivo, two neurological deteriorations 
occurred, consistent with flares of intracerebral oedema. These were managed with 
re-escalation of dexamethasone to 8 mg bd and cycle 2 was delayed by a week to 
enable dexamethasone to be weaned back to 4 mg bd. 
On cycle 2 day 1, the alanine aminotransferase (ALT) was elevated at 122 U/L (ULN 
<40 U/L). Treatment was administered with close monitoring of liver function. Due to 
a further rise in ALT to 186 U/L, dexamethasone was re-escalated to 8 mg bd. A 
presumptive diagnosis of immune-related transaminitis was made and other 
aetiologies were excluded. Given the steroid-refractory nature of the hepatitis, 
mycophenolate mofetil was initiated early and the ALT began to slowly fall over the 
next few weeks. 
Restaging imaging 8 weeks from cycle 1 demonstrated a mixed response with 
pseudoprogression in the liver but a notable reduction in the tonsils and cervical 
lymph nodes. The intracranial metastases were stable. The liver lesions were stable 
on subsequent imaging. After 6 months, without any further treatment, the patient 
had a maintained extracranial and intracranial response on scans and the ALT had 
normalised. Steroids have been reduced to prednisolone 5 mg and mycophenolate 
mofetil has been ceased. Imaging at 7 months, however, shows progression in his 
right ureter and in his brain. 
This case demonstrating disease control for 7 months highlights that durable benefit 
may be seen after treatment with ipi + nivo, even in patients with poor prognostic 
factors such as disease refractory to anti–PD-1 blockade, an elevated baseline LDH, 
active brain and leptomeningeal metastases and a need for prolonged 
immunosuppression. We hope that this report may also be of use to clinicians when 
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